

# Vibeke Strand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9564547/publications.pdf>

Version: 2024-02-01

282  
papers

18,850  
citations

18482

62  
h-index

13379

130  
g-index

294  
all docs

294  
docs citations

294  
times ranked

14427  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group. Seminars in Arthritis and Rheumatism, 2023, 58, 152028.	3.4	1
2	Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a <sc>52â€œWeek</sc>, Randomized, Controlled Trial. Arthritis Care and Research, 2022, 74, 451-460.	3.4	10
3	Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: <sc>Longâ€œTerm</sc> Results of Two Phase <sc>III</sc> Randomized Controlled Trials. Arthritis Care and Research, 2022, 74, 759-767.	3.4	10
4	Benefitâ€œrisk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain, 2022, 163, 1006-1018.	4.2	4
5	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 2022, 238, 430-437.	2.1	4
6	A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis. Rheumatology, 2022, 61, 2441-2449.	1.9	5
7	The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Seminars in Arthritis and Rheumatism, 2022, 52, 151939.	3.4	41
8	The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. Lancet Rheumatology, The, 2022, 4, e208-e219.	3.9	3
9	Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response. Current Rheumatology Reports, 2022, 24, 12-19.	4.7	4
10	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2022, , jrheum.211322.	2.0	1
11	Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. Lancet Rheumatology, The, 2022, 4, e198-e207.	3.9	7
12	Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritis. Expert Review of Clinical Immunology, 2022, 18, 193-205.	3.0	3
13	Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-â€œinhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis. Expert Review of Molecular Diagnostics, 2022, 22, 101-109.	3.1	6
14	Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease. Advances in Therapy, 2022, 39, 738-753.	2.9	8
15	The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases. Advances in Therapy, 2022, 39, 767-778.	2.9	1
16	Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. Rheumatology, 2022, 61, 3246-3256.	1.9	3
17	Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-â€œinhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis. Expert Opinion on Biological Therapy, 2022, 22, 801-807.	3.1	3
18	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	3.9	17

#	ARTICLE	IF	CITATIONS
19	Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open, 2022, 8, e002253.	3.8	14
20	Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology, 2021, 60, 3209-3221.	1.9	14
21	Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. Arthritis Care and Research, 2021, 73, 649-657.	3.4	6
22	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 58-66.	2.0	5
23	Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. Journal of Rheumatology, 2021, 48, 188-197.	2.0	7
24	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. Modern Rheumatology, 2021, 31, 534-542.	1.8	6
25	Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. Rheumatology and Therapy, 2021, 8, 135-150.	2.3	7
26	Relation Between Fatigue and ACR Response in Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitor Therapy: A Population-based Cohort Study. Journal of Rheumatology, 2021, 48, 829-835.	2.0	2
27	Immunogenicity of biologic agents in rheumatology. Nature Reviews Rheumatology, 2021, 17, 81-97.	8.0	43
28	The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. Journal of Allergy and Clinical Immunology, 2021, 147, 814-826.	2.9	70
29	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatology, 2021, 60, 1137-1147.	1.9	13
30	Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years. Lupus, 2021, 30, 578-586.	1.6	8
31	Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. RMD Open, 2021, 7, e001484.	3.8	1
32	Patient-Reported Outcomes in SLE. , 2021, , 213-227.		0
33	Upadacitinib improves patient-reported outcomes <i>vs</i> placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology, 2021, 60, 5583-5594.	1.9	17
34	RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?. RMD Open, 2021, 7, e001565.	3.8	4
35	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2021, , jrheum.201679.	2.0	2
36	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201668.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 367-386.	3.4	2
38	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1547-1551.	2.0	3
39	The Prognostic Value of Pain Phenotyping in Relation to Treatment Outcomes in Patients with Axial Spondyloarthritis Treated in Clinical Practice: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1469.	2.4	0
40	Long-term safety and efficacy of tofacitinib up to 48 months in psoriatic arthritis. <i>Lancet Rheumatology</i> , The, 2021, 3, e239-e240.	3.9	0
41	OMERACT 2020: A virtual (R)evolution. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 588-592.	3.4	0
42	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	3.4	7
43	Immune-mediated diseases and thromboembolic events: a modified Delphi panel. <i>Current Medical Research and Opinion</i> , 2021, 37, 1283-1291.	1.9	0
44	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	3.4	13
45	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 607-617.	3.4	3
46	Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019. <i>Drug Safety</i> , 2021, 44, 889-897.	3.2	34
47	Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated Diseases. <i>Clinical Therapeutics</i> , 2021, 43, 1392-1407.e1.	2.5	17
48	What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?. <i>Rheumatology</i> , 2021, 61, 6-7.	1.9	1
49	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	3.4	3
50	Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. <i>BMC Rheumatology</i> , 2021, 5, 35.	1.6	2
51	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1117-1124.	3.4	4
52	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1113-1116.	3.4	4
53	Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update. <i>Clinical Rheumatology</i> , 2021, 40, 3027-3037.	2.2	6
54	Fatigue and Pain Measurements in Systemic Lupus Erythematosus. , 2021, , 303-335.		0

#	ARTICLE	IF	CITATIONS
55	Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. <i>Rheumatology and Therapy</i> , 2021, 8, 1827-1844.	2.3	8
56	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , 2021, 8, 1789-1808.	2.3	14
57	Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e446-e455.	0.9	12
58	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab076.	0.7	4
59	Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data. <i>Current Medical Research and Opinion</i> , 2020, 36, 161-168.	1.9	6
60	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020, 34, 27-37.	4.6	35
61	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020, 29, 369-380.	3.1	2
62	P225â€fInhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patients with RA: one-year outcomes from the select Phase 3 programme. <i>Rheumatology</i> , 2020, 59, .	1.9	0
63	High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab. <i>Arthritis Research and Therapy</i> , 2020, 22, 250.	3.5	17
64	Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , 2020, 22, 177.	3.5	9
65	P213â€fHigh baseline serum IL-6 predicts increased sarilumab treatment response for patient reported symptoms and health-related quality of life among RA patients with inadequate response to MTX. <i>Rheumatology</i> , 2020, 59, .	1.9	0
66	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. <i>Pain</i> , 2020, 161, 2446-2461.	4.2	64
67	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	3.4	6
68	Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib. <i>Arthritis Research and Therapy</i> , 2020, 22, 243.	3.5	17
69	Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. <i>Lupus Science and Medicine</i> , 2020, 7, e000373.	2.7	25
70	New Treatments in Rheumatology: Biosimilars. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 325-336.	1.4	2
71	Infections in the Era of Targeted Therapies: Mapping the Road Ahead. <i>Frontiers in Medicine</i> , 2020, 7, 336.	2.6	5
72	Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. <i>Rheumatology and Therapy</i> , 2020, 7, 759-774.	2.3	6

#	ARTICLE	IF	CITATIONS
73	Minimizing efficacy differences between phase II and III RCTs. Nature Reviews Rheumatology, 2020, 16, 359-360.	8.0	0
74	Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD Open, 2020, 6, e001240.	3.8	20
75	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. Arthritis and Rheumatology, 2020, 72, 1607-1620.	5.6	126
76	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. Rheumatology International, 2020, 40, 1021-1028.	3.0	3
77	Biosimilars. , 2020, , 411-424.		1
78	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clinical and Experimental Rheumatology, 2020, 38, 848-857.	0.8	6
79	The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study. Arthritis Research and Therapy, 2019, 21, 221.	3.5	11
80	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis and Rheumatology, 2019, 71, 878-891.	5.6	64
81	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. Journal of Rheumatology, 2019, 46, 1159-1163.	2.0	11
82	Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies. Patient Related Outcome Measures, 2019, Volume 10, 1-7.	1.2	19
83	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1028-1035.	2.0	61
84	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. Journal of Rheumatology, 2019, 46, 1053-1058.	2.0	8
85	Reply. Arthritis and Rheumatology, 2019, 71, 1590-1592.	5.6	0
86	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. Journal of Rheumatology, 2019, 46, 1173-1178.	2.0	6
87	Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open, 2019, 5, e000889.	3.8	27
88	Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. Journal of Rheumatology, 2019, 46, 1259-1267.	2.0	9
89	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 1164-1167.	2.0	7
90	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. Journal of Rheumatology, 2019, 46, 996-1005.	2.0	36

#	ARTICLE	IF	CITATIONS
91	Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 61.	3.5	44
92	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	2.0	97
93	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	2.0	65
94	Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. <i>Arthritis Research and Therapy</i> , 2019, 21, 64.	3.5	31
95	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019, 46, 1006-1013.	2.0	34
96	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broadenâ€”a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , 2019, 5, e000806.	3.8	44
97	Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. <i>RMD Open</i> , 2019, 5, e000808.	3.8	46
98	Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. <i>RMD Open</i> , 2019, 5, e001017.	3.8	9
99	54â€”Blood concentrations of complement split product iC3b and serum C3 associate with systemic lupus erythematosus disease activity. , 2019, , .		0
100	THU0414â€”COMPARISON OF INTRA-ARTICULAR SHAM AND VEHICLE INJECTIONS FROM A PHASE 2B TRIAL OF SMO4690, A SMALL-MOLECULE WNT PATHWAY INHIBITOR FOR KNEE OSTEOARTHRITIS. , 2019, , .		0
101	Measurement properties of the minimal disease activity criteria for psoriatic arthritis. <i>RMD Open</i> , 2019, 5, e001002.	3.8	19
102	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. <i>RMD Open</i> , 2019, 5, e001040.	3.8	28
103	Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. <i>Arthritis Research and Therapy</i> , 2019, 21, 263.	3.5	29
104	Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. <i>Arthritis Research and Therapy</i> , 2019, 21, 272.	3.5	29
105	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	1.9	16
106	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
107	Longâ€”Term Impact of Belimumab on Healthâ€”Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. <i>Arthritis Care and Research</i> , 2019, 71, 829-838.	3.4	32
108	Association of Blood Concentrations of Complement Split Product <sc>iC</sc>3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity. <i>Arthritis and Rheumatology</i> , 2019, 71, 420-430.	5.6	39

#	ARTICLE	IF	CITATIONS
109	A Single Intra-Articular Injection of Gel-200 for Treatment of Symptomatic Osteoarthritis of the Knee Is More Effective than Phosphate Buffered Saline at 6 Months: A Subgroup Analysis of a Multicenter, Randomized Controlled Trial. <i>Cartilage</i> , 2019, 10, 417-422.	2.7	17
110	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.0	14
111	Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 260-269.	0.8	12
112	Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. <i>Clinical Rheumatology</i> , 2018, 37, 2043-2053.	2.2	9
113	Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials. <i>Arthritis and Rheumatology</i> , 2018, 70, 1450-1458.	5.6	18
114	Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 495-499.	0.9	10
115	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	30.5	1,441
116	Adiposity in Juvenile Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 411-418.	2.0	15
117	Comparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 125-133.	3.4	35
118	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e23-e23.	0.9	16
119	Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study. <i>Arthritis Care and Research</i> , 2018, 70, 1206-1217.	3.4	4
120	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.4	50
121	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. <i>Arthritis Research and Therapy</i> , 2018, 20, 265.	3.5	29
122	Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 269.	3.5	9
123	170- Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved low disease activity related to psoriatic arthritis disease activity score. <i>Rheumatology</i> , 2018, 57, .	1.9	0
124	Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs. <i>Rheumatology and Therapy</i> , 2018, 5, 475-498.	2.3	8
125	182- Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved disease activity index for psoriatic arthritis remission. <i>Rheumatology</i> , 2018, 57, .	1.9	0
126	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 246.	2.6	20

#	ARTICLE	IF	CITATIONS
127	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018, 5, 341-353.	2.3	9
128	A Pooled Analysis of Two Multicenter, Randomized Controlled Trials of a Single Intra-articular Injection of Gel-200 for Treatment of Osteoarthritis of the Knee. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2018, 11, 117954411877306.	1.2	3
129	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000602.	3.8	13
130	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , 2018, 57, 1777-1788.	1.9	27
131	Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 344-352.	0.9	20
132	Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018, 20, 113.	3.5	24
133	Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity. <i>RMD Open</i> , 2018, 4, e000695.	3.8	6
134	Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal Phase III clinical trial data. <i>Rheumatology</i> , 2018, 57, .	1.9	0
135	Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 129.	3.5	31
136	Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies. <i>Rheumatology</i> , 2018, 57, .	1.9	1
137	Functional impairment measurement in psoriatic arthritis: Importance and challenges. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 436-448.	3.4	29
138	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
139	Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2018, 5, 216-223.	0.6	8
140	The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. <i>Current Medical Research and Opinion</i> , 2017, 33, 993-1003.	1.9	25
141	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
142	Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 992-997.	0.9	17
143	Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naïve Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 863-865.	5.6	9
144	Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1495-1501.	0.9	63

#	ARTICLE	IF	CITATIONS
145	Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease. Mayo Clinic Proceedings, 2017, 92, 555-564.	3.0	27
146	Importance of "meeting of the minds"™: patient-reported outcomes and MRI. Annals of the Rheumatic Diseases, 2017, 76, 473-475.	0.9	4
147	Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Annals of the Rheumatic Diseases, 2017, 76, 203-207.	0.9	78
148	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Annals of the Rheumatic Diseases, 2017, 76, 534-542.	0.9	111
149	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Annals of the Rheumatic Diseases, 2017, 76, 673-680.	0.9	194
150	Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept. Rheumatology and Therapy, 2017, 4, 99-109.	2.3	3
151	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2017, 44, 697-700.	2.0	42
152	Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs, 2017, 31, 299-316.	4.6	241
153	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. Journal of Rheumatology, 2017, 44, 1894-1898.	2.0	12
154	Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. RMD Open, 2017, 3, e000416.	3.8	33
155	Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. Journal of Medical Economics, 2017, 20, 703-714.	2.1	15
156	Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology, 2017, 56, 46-57.	1.9	79
157	Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. RMD Open, 2017, 3, e000496.	3.8	16
158	Patient Burden of Axial Spondyloarthritis. Journal of Clinical Rheumatology, 2017, 23, 383-391.	0.9	85
159	Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry. Rheumatology and Therapy, 2017, 4, 489-502.	2.3	51
160	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1884-1888.	2.0	11
161	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. Journal of Rheumatology, 2017, 44, 1551-1559.	2.0	27
162	Discordant patient "physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis. RMD Open, 2017, 3, e000551.	3.8	17

#	ARTICLE	IF	CITATIONS
163	The Role of Patient-Reported Outcomes in Systemic Lupus Erythematosus. Current Treatment Options in Rheumatology, 2017, 3, 308-321.	1.4	12
164	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. Journal of Rheumatology, 2017, 44, 1916-1919.	2.0	11
165	Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. Arthritis Care and Research, 2017, 69, 592-598.	3.4	62
166	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). Patient, 2017, 10, 141-152.	2.7	41
167	Evidence for safety of retreatment with a single intra-articular injection of Gel-200 for treatment of osteoarthritis of the knee from the double-blind pivotal and open-label retreatment clinical trials. BMC Musculoskeletal Disorders, 2016, 17, 240.	1.9	16
168	Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Research and Therapy, 2016, 18, 114.	3.5	49
169	Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain, 2016, 157, 1836-1850.	4.2	152
170	Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry. Arthritis Care and Research, 2016, 68, 914-921.	3.4	5
171	Ms. A.M. Taylor, et al reply. Journal of Rheumatology, 2016, 43, 826.2-827.	2.0	0
172	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open, 2016, 2, e000217.	3.8	35
173	The changing landscape of biosimilars in rheumatology. Annals of the Rheumatic Diseases, 2016, 75, 974-982.	0.9	160
174	Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open, 2016, 2, e000308.	3.8	50
175	Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. RMD Open, 2016, 2, e000232.	3.8	16
176	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology, 2016, 55, 1031-1041.	1.9	62
177	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Research and Therapy, 2016, 18, 198.	3.5	56
178	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. Journal of Rheumatology, 2016, 43, 965-969.	2.0	24
179	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Safety, 2016, 39, 755-762.	3.2	112
180	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter - Determining Validation Requirements. Journal of Rheumatology, 2016, 43, 208-213.	2.0	30

#	ARTICLE	IF	CITATIONS
181	The term “non-radiographic axial spondyloarthritis”™ is much more important to classify than to diagnose patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 791-794.	0.9	105
182	Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 362.	3.5	181
183	Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. <i>Journal of Pain Research</i> , 2015, 8, 217.	2.0	79
184	Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial. <i>Arthritis Care and Research</i> , 2015, 67, 475-483.	3.4	50
185	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. <i>Arthritis Research and Therapy</i> , 2015, 17, 307.	3.5	53
186	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. <i>Journal of Rheumatology</i> , 2015, 42, 1943-1946.	2.0	8
187	Enhanced Patient Involvement and the Need to Revise the Core Set “ Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	2.0	34
188	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) “ Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , 2015, 42, 2168-2171.	2.0	142
189	Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety study. <i>Postgraduate Medicine</i> , 2015, 127, 517-528.	2.0	9
190	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 1640-1649.	1.9	13
191	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. <i>Journal of Rheumatology</i> , 2015, 42, 1947-1953.	2.0	20
192	Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2046-2054.	2.0	58
193	Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. <i>Journal of Rheumatology</i> , 2015, 42, 1962-1970.	2.0	116
194	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. <i>Journal of Rheumatology</i> , 2015, 42, 1934-1942.	2.0	7
195	Assessing disease activity and outcome in systemic lupus erythematosus. , 2015, , 1093-1098.		0
196	Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. <i>Lupus Science and Medicine</i> , 2014, 1, e000031.	2.7	63
197	Development and Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Assess and Monitor the Impact of Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2014, 66, 1542-1550.	3.4	45
198	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 183-190.	0.9	266

#	ARTICLE	IF	CITATIONS
199	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. <i>Rheumatology</i> , 2014, 53, 502-511.	1.9	64
200	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	2.0	54
201	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	5.0	625
202	Putting the value into biosimilar decision making. <i>Autoimmunity Reviews</i> , 2014, 13, 678-684.	5.8	23
203	Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 838-844.	0.9	123
204	Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 514-520.	0.6	64
205	Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 31.	2.4	17
206	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
207	Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase Ib randomized, controlled study. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 82.	2.4	63
208	Predictors of self-reported health-related quality of life in systemic lupus erythematosus. <i>Rheumatology</i> , 2013, 52, 1651-1657.	1.9	53
209	Review: The Utility of Magnetic Resonance Imaging for Assessing Structural Damage in Randomized Controlled Trials in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2513-2523.	6.7	40
210	Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study. <i>Journal of Rheumatology</i> , 2013, 40, 1158-1165.	2.0	42
211	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 322-328.	0.9	166
212	Response to M. Boers's concerns about spidergrams. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 247-252.	5.0	3
213	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013, 52, 1313-1322.	1.9	115
214	Prevalence of Axial Spondyloarthritis in United States Rheumatology Practices: Assessment of SpondyloArthritis International Society Criteria Versus Rheumatology Expert Clinical Diagnosis. <i>Arthritis Care and Research</i> , 2013, 65, 1299-1306.	3.4	78
215	Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. <i>Rheumatology</i> , 2012, 51, 1628-1638.	1.9	38
216	Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1143-1150.	0.9	129

#	ARTICLE	IF	CITATIONS
217	Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2012, 39, 1450-1457.	2.0	59
218	Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. <i>Rheumatology</i> , 2012, 51, 1860-1869.	1.9	85
219	Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. <i>Journal of Rheumatology</i> , 2012, 39, 63-72.	2.0	58
220	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1855-1860.	0.9	131
221	Measuring outcomes in systemic lupus erythematosus clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 455-468.	1.4	40
222	OMERACT 10 Sharp Symposium: Important Findings in Examination of Imaging Methods for Measurement of Joint Damage in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2009-2013.	2.0	4
223	Effect of Blood Loss on Physical Function in Arthritis Patients: A Pooled Analysis. <i>Health Outcomes Research in Medicine</i> , 2011, 2, e27-e38.	0.6	4
224	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
225	Treatment of Osteoarthritis with Continuous Versus Intermittent Celecoxib. <i>Journal of Rheumatology</i> , 2011, 38, 2625-2634.	2.0	26
226	Damage and Progression on Radiographs in Individual Joints: Data from Pivotal Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2011, 38, 2018-2022.	2.0	20
227	Generic Versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2011, 38, 1821-1823.	2.0	20
228	High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 785-791.	0.9	269
229	Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1277-1281.	0.9	22
230	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 996-1002.	0.9	60
231	Magnetic Resonance Imaging in Rheumatoid Arthritis Clinical Trials: Emerging Patterns Based on Recent Experience. <i>Journal of Rheumatology</i> , 2011, 38, 2023-2030.	2.0	15
232	AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2010, 106, 873-884.	1.6	21
233	Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. <i>Rheumatology</i> , 2010, 49, 1900-1910.	1.9	55
234	Newer Biological Agents in Rheumatoid Arthritis. <i>Drugs</i> , 2010, 70, 121-145.	10.9	111

#	ARTICLE	IF	CITATIONS
235	A first step to assess harm and benefit in clinical trials in one scale. Journal of Clinical Epidemiology, 2010, 63, 627-632.	5.0	25
236	The impact of rheumatoid arthritis and treatment on patients' lives. Clinical and Experimental Rheumatology, 2010, 28, S32-40.	0.8	68
237	Spondyloarthritis Is Associated with Poor Function and Physical Health-Related Quality of Life. Journal of Rheumatology, 2009, 36, 1012-1020.	2.0	96
238	Novel evidence-based systemic lupus erythematosus responder index. Arthritis and Rheumatism, 2009, 61, 1143-1151.	6.7	397
239	Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis and Rheumatism, 2009, 61, 1592-1600.	6.7	78
240	Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Research and Therapy, 2009, 11, R170.	3.5	78
241	Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Research and Therapy, 2009, 11, 205.	3.5	34
242	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism, 2008, 58, 3319-3329.	6.7	539
243	Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort. American Journal of Medicine, 2008, 121, 532-538.	1.5	32
244	Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. American Journal of Managed Care, 2008, 14, 234-54.	1.1	82
245	Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet, The, 2007, 370, 2138-2151.	13.7	145
246	OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials, 2007, 8, 38.	1.6	420
247	Biologic therapies in rheumatology: lessons learned, future directions. Nature Reviews Drug Discovery, 2007, 6, 75-92.	46.4	178
248	Lessons learned from clinical trials in SLE. Autoimmunity Reviews, 2007, 6, 209-214.	5.8	23
249	A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus. Current Rheumatology Reports, 2007, 9, 427-430.	4.7	2
250	Health-related quality of life in patients with systemic lupus erythematosus: an update. Annals of the Academy of Medicine, Singapore, 2007, 36, 115-22.	0.4	44
251	Selective T-cell costimulation modulation: a new approach to treating rheumatoid arthritis. American Journal of Orthopedics, 2007, 36, 8, 13-4.	0.7	0
252	Worker productivity outcome measures in arthritis. Journal of Rheumatology, 2007, 34, 1372-80.	2.0	90

#	ARTICLE	IF	CITATIONS
253	Interleukin-6 inhibition--tolerability profile and clinical implications. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65 Suppl 1, S21-4.	0.7	1
254	Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. American Journal of Managed Care, 2007, 13 Suppl 9, S237-51.	1.1	36
255	Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets. Drug Information Journal, 2006, 40, 111-116.	0.5	2
256	Relationship between anti-“double”-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 1129-1137.	6.7	187
257	Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 317-326.	1.4	72
258	Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 583-9.	2.0	50
259	Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 590-601.	2.0	68
260	Outcome measures in osteoarthritis: Randomized controlled trials. Current Rheumatology Reports, 2004, 6, 20-30.	4.7	54
261	Counterpoint from the trenches: A pragmatic approach to therapeutic trials in rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 1344-1347.	6.7	9
262	Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 50, 2858-2868.	6.7	133
263	Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis. American Journal of Therapeutics, 2004, 11, 244-250.	0.9	71
264	Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. Journal of Rheumatology, 2004, 31, 1521-31.	2.0	65
265	Radiographic data from recent randomized controlled trials in rheumatoid arthritis: What have we learned?. Arthritis and Rheumatism, 2003, 48, 21-34.	6.7	64
266	LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. Arthritis and Rheumatism, 2003, 48, 442-454.	6.7	222
267	Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety) Tj ETQq1 1 0.784314 rgBT3/5 overlod	10.7	411
268	Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. Annals of Internal Medicine, 2002, 137, 726.	3.9	287
269	Leflunomide for the treatment of rheumatoid arthritis. The Cochrane Library, 2002, , CD002047.	2.8	44
270	Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism, 2002, 46, 1820-1829.	6.7	149

#	ARTICLE	IF	CITATIONS
271	The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis and Rheumatism, 2002, 47, 349-355.	6.7	63
272	New therapies in development for autoimmune diseases: their rationale for combination treatment. Seminars in Immunopathology, 2001, 23, 43-61.	4.0	3
273	Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis and Rheumatism, 2001, 44, 1984-1992.	6.7	275
274	Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis and Rheumatism, 2000, 43, 506.	6.7	155
275	Recent Developments for Optimal End-Points in Rheumatoid Arthritis Clinical Studies. Disease Management and Health Outcomes, 2000, 8, 87-97.	0.4	3
276	Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate. Archives of Internal Medicine, 1999, 159, 2542.	3.8	614
277	Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis and Rheumatism, 1999, 42, 1870-1878.	6.7	132
278	Clinical response to nonsteroidal antiinflammatory drugs. Arthritis and Rheumatism, 1997, 40, 1940-1943.	6.7	15
279	American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism, 1995, 38, 727-735.	6.7	2,531
280	059â€ŒThe Impact of Intensive Treatment, Inflammation and Remission on Health-Related Quality of Life in Early and Established Rheumatoid Arthritis. Rheumatology, 0, , .	1.9	0
281	Knowledge Translation for Patients: Methods to Support Patients' Participation in Decision making about Preference-Sensitive Treatment Options in Rheumatology. , 0, , 41-62.		1
282	OMERACT: An Ongoing Evidence-Based Initiative to Improve the Quality of Outcome Measures in Rheumatology. , 0, , 19-24.		1